Sangamo Therapeutics draws $7 million in bankruptcy financing
Sangamo Therapeutics posted a $14.45 million August 2026 loss in its Chapter 11 operating report filed October 14. Restructuring expenses totaled $9.98 million, while month-end cash reached $23.23 million. A $7 million draw on August 21 came under the replacement debtor-in-possession term loan facility, authorized for up to $35 million. Equipment sales closed around August 20, generating $2.3 million in cash proceeds and a $250,000 offset against DIP Obligations. The August 31 balance sheet showed a $6.73 million stockholders' equity deficit. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-423054), on October 16, 2026, and is solely responsible for the information contained therein. (C)
Sangamo Therapeutics posted a $14.45 million August 2026 loss in its Chapter 11 operating report filed October 14. Restructuring expenses totaled $9.98 million, while month-end cash reached $23.23 million. A $7 million draw on August 21 came under the replacement debtor-in-possession term loan facility, authorized for up to $35 million. Equipment sales closed around August 20, generating $2.3 million in cash proceeds and a $250,000 offset against DIP Obligations.
The August 31 balance sheet showed a $6.73 million stockholders' equity deficit. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc.
published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-423054), on October 16, 2026, and is solely responsible for the information contained therein. (C)